Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atigotatug (BMS-986012) in small cell lung cancer
NCT02949895Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Atigotatug in small cell lung cancer (SCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events (AEs) up to 2 years, Number of participants with serious adverse events (SAEs) up to 2 years and 3 more. Started Nov 2016; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02949895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949895.